ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,804.50
0.14%
S&P ASX All Technology
3,082.20
0.46%
Brent Oil
82.935
0.08%
US Dollar vs AUD
1.52148
0.25%
Bitcoin
62,575.95
0.39%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Transgene SA (TNG)

  7. Transgene SA (TNG) News

TNG

Transgene (TNG)

Transgene SA
Date:
Sort by:
 Showing the most relevant articles for your search:EU:TNG
DateTimeSourceHeadlineSymbolCompany
25/04/202401:45GlobeNewswire Inc.Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024EU:TNGTransgene SA
25/04/202401:45GlobeNewswire Inc.Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024EU:TNGTransgene SA
25/04/202401:45GlobeNewswire Inc.Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024EU:TNGTransgene SA
12/04/202403:05GlobeNewswire Inc.Document d'enregistrement Universel 2023EU:TNGTransgene SA
12/04/202401:45GlobeNewswire Inc.Availability of Transgene's 2023 Universal Registration DocumentEU:TNGTransgene SA
12/04/202401:45GlobeNewswire Inc.MIse à disposition du document d'enregistrement universel 2023 de TransgeneEU:TNGTransgene SA
10/04/202401:45GlobeNewswire Inc.Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024EU:TNGTransgene SA
10/04/202401:45GlobeNewswire Inc.Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024EU:TNGTransgene SA
10/04/202401:45GlobeNewswire Inc.Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024EU:TNGTransgene SA
28/03/202403:45GlobeNewswire Inc.Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources OfficerEU:TNGTransgene SA
28/03/202403:45GlobeNewswire Inc.Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025EU:TNGTransgene SA
28/03/202403:45GlobeNewswire Inc.Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025EU:TNGTransgene SA
28/03/202403:45GlobeNewswire Inc.Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources OfficerEU:TNGTransgene SA
28/03/202403:45GlobeNewswire Inc.Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources HumainesEU:TNGTransgene SA
28/03/202403:45GlobeNewswire Inc.Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025EU:TNGTransgene SA
19/03/202403:45GlobeNewswire Inc.Transgene annonce ses prochaines rencontres avec les investisseursEU:TNGTransgene SA
19/03/202403:45GlobeNewswire Inc.Transgene Announces Upcoming Investor MeetingsEU:TNGTransgene SA
19/03/202403:45GlobeNewswire Inc.Transgene Announces Upcoming Investor MeetingsEU:TNGTransgene SA
06/03/202417:30GlobeNewswire Inc.Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024EU:TNGTransgene SA
06/03/202417:30GlobeNewswire Inc.Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024EU:TNGTransgene SA
06/03/202417:30GlobeNewswire Inc.Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024EU:TNGTransgene SA
05/03/202417:30GlobeNewswire Inc.Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050EU:TNGTransgene SA
05/03/202417:30GlobeNewswire Inc.Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050EU:TNGTransgene SA
05/03/202417:30GlobeNewswire Inc.Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050EU:TNGTransgene SA
23/01/202403:45GlobeNewswire Inc.Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business OfficerEU:TNGTransgene SA
23/01/202403:45GlobeNewswire Inc.Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business OfficerEU:TNGTransgene SA
23/01/202403:45GlobeNewswire Inc.Transgene annonce la nomination de James Wentworth comme Directeur du Business DevelopmentEU:TNGTransgene SA
22/01/202418:00GlobeNewswire Inc.Transgene Announces Financial Calendar for 2024EU:TNGTransgene SA
22/01/202418:00GlobeNewswire Inc.Transgene Announces Financial Calendar for 2024EU:TNGTransgene SA
22/01/202418:00GlobeNewswire Inc.Transgene présente son calendrier de communication financière pour 2024EU:TNGTransgene SA
 Showing the most relevant articles for your search:EU:TNG

Your Recent History

FX
GBPAUD
Sterling vs AUD
FX
AUDUSD
AUD vs US Dollar
NYSE
KO
Coca Cola
ASX
CBA
Commonwealth Bank Of Aus...
NYSE
JPM
JP Morgan Chase
ASX
FMG
Fortescue
COIN
BTCUSD
Bitcoin
ASX
XFL
S&P ASX 50
NYSE
MCD
McDonalds
ASX
XJO
S&P ASX 200
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
MSFT
Microsoft
ASX
BHP
BHP
ASX
TLS
Telstra
FX
AUDCAD
AUD vs CAD
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved